P
Penumbra
Penumbra develops clinically beneficial products that help patients suffering from stroke and other neurovascular diseases
At a glance
- Founded
- 2004
- Headquarters
- Alameda, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Penumbra.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Alumni founders
Former Penumbra employees who went on to found companies, sorted by Dealroom signal score.
Surbhi SarnaUnited States
Ryan CornielUnited States
PAPersist AIEst. 2022
Karthik Raman, PhDUnited States
ITInterline TherapeuticsEst. 2020Global footprint
team presence
across markets
Patents
45 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Penumbra on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Penumbra on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.